Twitter

Posts Tagged ‘jiangsu’


A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Conditions :   Breast Cancer;   Neutropenia;   Febrile Neutropenia Interventions :   Drug: Drug: Pegylated rhG-CSF: 100µg/kg;   Drug: Pegylated rhG-CSF: 6mg;   Drug: rhG-CSF 5ug/kg/day Sponsors :   Jiangsu HengRui Medicine Co., Ltd.;   Jiangsu HengRui Medicine Co., Ltd. Recruiting – verified May 2012

Read More...

A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy

Conditions :   NSCLC;   Neutropenia;   Febrile Neutropenia Interventions :   Drug: Pegylated rhG-CSF: 100µg/kg;   Drug: Pegylated rhG-CSF: 6mg;   Drug: placebo and rhG-CSF 5ug/kg/d Sponsor :   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting – verified March 2012

Read More...

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Condition :   Non-Small Cell Lung Cancer Interventions :   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Endostar;   Drug: Centrum Sponsor :   Jiangsu Simcere Pharmaceutical R&D Co. Ltd. Recruiting – verified February 2012

Read More...

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer

Condition :   Colorectal Cancer Interventions :   Drug: Apatinib;   Drug: apatinib Sponsors :   Jiangsu HengRui Medicine Co., Ltd.;   Fudan University Recruiting – verified February 2012

Read More...

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Condition :   Advanced or Metastatic Gastric Cancer Interventions :   Drug: apatinib;   Drug: placebo Sponsors :   Jiangsu HengRui Medicine Co., Ltd.;   Fudan University;   No.81 Hospital of the PLA Recruiting – verified January 2012

Read More...

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Condition :   Myelogenous Leukemia, Chronic Interventions :   Drug: flumatinib;   Drug: imatinib Sponsor :   Jiangsu HengRui Medicine Co., Ltd. Active, not recruiting – verified January 2012

Read More...

Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma

Condition :   Locally Advanced Nasopharyngeal Carcinoma Interventions :   Drug: Famitinib;   Drug: Cisplatin;   Radiation: radiation Sponsors :   Jiangsu HengRui Medicine Co., Ltd.;   Sun Yat-sen University Recruiting – verified October 2011

Read More...

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Condition :   Advanced Solid Cancer Intervention :   Drug: henatinib Sponsor :   Jiangsu HengRui Medicine Co., Ltd. Recruiting – verified August 2011

Read More...

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Condition :   Non-small Cell Lung Cancer Interventions :   Drug: Gefitinib;   Drug: Vinorelbine/Cisplatin Sponsors :   Guangdong Association of Clinical Trials;   Guangdong General Hospital;   First Affiliated Hospital, Sun Yat-Sen University;   Sun Yat-sen University;   Jilin Cancer Hospital;   Liaoning Cancer Hospital;   The First Affiliated Hospital of China Medical University;   Chinese PLA General Hospital;   Peking Union Medical College Hospital;   Peking University People’s Hospital;   Beijing Chest Hospital;   309th hospital of PLA;   Beijing Cancer Hospital;   Peking University First Hospital;   Tianjin Medical University Cancer Institute and Hospital;   The affiliated Hospital of medical college qingdao University,China;   Jiangsu Cancer Hospital, China;   the First Affiliated Hospital of Soochow University;   Zhongshan Hospital, Fudan University;   Shanghai Pulmonary Hospital;   Zhejiang Cancer Hospital;   The First Affiliated Hospital of Medical College of Zhejiang University;   Wuhan Union Hospital, China;   Wuhan Tonggi Hospital;   West China Hospital;   Tang-Du Hospital Recruiting – verified July 2011

Read More...

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Conditions :   Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma Intervention :   Drug: Famitinib Sponsors :   Jiangsu HengRui Medicine Co., Ltd.;   Department of Medical Oncology, Cancer Center, Sun Yet Sen University Recruiting – verified July 2011

Read More...